Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 5/20 | 0.47 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2101388 | 0.89 | MAPT (0.49) | MAPTTHRBTP53SMN1; SMN2 | |
| SCHEMBL2098878 | 0.89 | DPP4 (0.50) | DPP4PADI4MAP4K4JAK3BTK | |
| SCHEMBL2098876 | 0.89 | DPP4 (0.50) | DPP4PADI4MAP4K4JAK3BTK | |
| SCHEMBL2097778 | 0.89 | DPP4 (0.49) | TP53DPP4PADI4MAP4K4JAK3 | |
| SCHEMBL2097781 | 0.89 | DPP4 (0.49) | TP53DPP4PADI4MAP4K4JAK3 | |
| SCHEMBL3150575 | 0.83 | DPP4 (0.49) | DPP4PADI4MAP4K4JAK3BTK | |
| Hydrochloric Acid SCHEMBL2098557 | 0.83 | MAPT (0.51) | MAPTTHRBTP53DPP4SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2098558 | 0.83 | MAPT (0.51) | MAPTTHRBTP53DPP4SMN1; SMN2 | |
| SCHEMBL3145390 | 0.83 | DPP4 (0.48) | DPP4PADI4MAP4K4JAK3BTK | |
| SCHEMBL2099460 | 0.83 | DPP4 (0.48) | DPP4PADI4MAP4K4JAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163774-B2 | Antidiabetic agents; 2-(amino-substituted piperidin-1-yl)benzimidazoles; N-(4-Chlorobenzyl)-2-(3-aminopiperidin-1-yl)-1-(4-fluorobenzyl)-1H-benzimidazole-6-carboxamide hydrochloride for example; use in combination with other antidiabetic, antilipemic agents | SANOFI-AVENTIS (FR) | 2012-04-24 | — | — | US | disclosed |
| US-20080090868-A1 | AMIDE-SUBSTITUTED 8 N BENZIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090868-A1 | AMIDE-SUBSTITUTED 8 N BENZIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | DPP8, GPR119, ABAT | MAPT 4405/4885THRB 2262/4885TP53 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.